BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang Y, Deng S, Xu J. Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets. Cancer Biol Med 2020;17:583-98. [PMID: 32944392 DOI: 10.20892/j.issn.2095-3941.2020.0066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu Z, Zhang Y, Xiang Y, Kang X. Small-Molecule PROTACs for Cancer Immunotherapy. Molecules 2022;27:5439. [DOI: 10.3390/molecules27175439] [Reference Citation Analysis]
2 Békés M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov 2022. [PMID: 35042991 DOI: 10.1038/s41573-021-00371-6] [Cited by in Crossref: 89] [Cited by in F6Publishing: 70] [Article Influence: 89.0] [Reference Citation Analysis]
3 Tundo GR, Sbardella D, Oddone F, Kudriaeva AA, Lacal PM, Belogurov AA Jr, Graziani G, Marini S. At the Cutting Edge against Cancer: A Perspective on Immunoproteasome and Immune Checkpoints Modulation as a Potential Therapeutic Intervention. Cancers (Basel) 2021;13:4852. [PMID: 34638337 DOI: 10.3390/cancers13194852] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
4 Xu J, Brosseau JP, Shi H. Targeted degradation of immune checkpoint proteins: emerging strategies for cancer immunotherapy. Oncogene 2020;39:7106-13. [PMID: 33024277 DOI: 10.1038/s41388-020-01491-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]